Partner Matters resent due to an error in the New Partners section, please read and retain this newsletter and discard the previous version. Many thanks |
|
|
Welcome To Our New Modality Partners |
|
|
It is a pleasure to announce that we have a number of new Partners, both new and existing Modality colleagues.
Birmingham
Dr Jenieve Lee
Dr Sachin Sudera
|
|
|
|
|
East Surrey
Dr Joydip Patel
|
|
Birmingham
Dr Lindsay Smith
|
|
Birmingham
Dr Mohamed Saleh
|
|
Birmingham
Dr Rania Salama
|
|
Birmingham
Dr Jasminder Matharu
|
|
Partnership Structure Review |
|
|
In line with our strategy, the partnership has successfully grown and diversified. As part of our ongoing development, we have completed a review of our existing partnership structure (along with the various entities we have setup over the years) and sought advice from Gateleys on how we should setup for the future.
The recommendation is for us to reorganise around our core partnership (Modality No 1 partnership) and establish another partnership (Modality No 2 partnership) which will pull all of our different business ventures under one umbrella as shown in the graphic below.
|
|
|
The proposed future state design maintains the liability protection for ventures we undertake and also gives us flexibility for the introduction of new partner types (i.e., consultant partners and strategic collaborators) and any exit options as and when they arise.
Underpinning our future state setup will be two partnership agreements – one for Modality No 1 Partnership and the other for Modality No 2 Partnership. For Modality No 1 Partnership, it will essentially be the core agreement from July 2019 but refined and refreshed based on feedback accumulated since the last update. Modality No 2 Partnership will be a new agreement but it will have common elements from our core Modality No 1 Partnership Agreement.
We are seeking your input on the updated partnership documents. You will find them on FutureNHS:
For ease of review, we have included a clean version, another with tracked changes and a summary of the changes for paperwork relating to Modality No 1 Partnership. In the case of Modality No 2 Partnership, we have the proposed agreement and a Frequently Asked Questions document. For your convenience, the most current agreement (last updated July 2019) is also available.
Any queries / feedback should be logged using the Feedback / Queries button. This will make it a lot simpler for us to track and also to provide a response back to each item raised. THANK YOU all in advance for your time and help with this. Our plan is to finalise this important effort of getting your feedback / input by the end of February.
|
|
|
Digital Transformation Update |
|
|
Our group digital transformation programme is making progress. We have established the key foundations for success: integration with EMIS and SystmOne via an “API” (Application Programming Interface), effective data flows to NHSE’s data platform, the development of our “PADU” framework to improve harmonisation and efficiency (Please see: PADUs - Modality Group - Modality (future.nhs.uk) video shown below).
|
|
|
The creation of a national team with bot programming and data expertise, exciting business partnerships with GOQii, LiberateAI and Google and close working relationships with Klinik, Edenbridge and Ada on data insights and the “digital front door”. In the short term, we are focussed on deploying RPA (“Robotic Process Automation”) to file pathology results, with excellent progress made across a number of sites using EMIS and a similar service coming online across our SystmOne divisions soon.
The next step will be to use algorithms on GOQii’s platform to accelerate and streamline this process, a we are particularly excited by prospect of being able to safely interpret and process the majority of long term condition blood test results in the coming months. Our second key priority is document administration, which will be transformed over the coming year as we merge our existing document management teams and deploy bots and AI technologies to read and file incoming correspondence from 111 and A&E.
GOQii and LiberateAI are doing exciting work on Call / Recall, with the opportunity to model demand and capacity for long term condition appointments, automate invites for some routine appointments, display real time data on long term condition care and integrate more effectively with our virtual coaching offer. The complexity of this area means it will take time to see direct impact in our day to day operations, but the potential is significant. In the short term, Edenbridge are working on our health data in order to delivery insights that will help you better understand what is happening in your practices and improve care in a number of areas. In Lewisham and AWC, our teams are deploying Klinik as a total digital access solution, to test whether an effective “digital front door”, can be engineered. To spread best practice, we have authored a “playbook on digital access”, which will be shared once the learning (good and bad!) from AWC and Lewisham is captured. As well as working with Klinik, and meeting with other emerging suppliers of online consultation and access software, we are also deploying Ada’s AI to test whether it can effectively triage musculoskeletal cases.
Much of 2022 was spent doing the “hard yards” – meeting and testing potential suppliers / partners, getting our infrastructure right and building our team. We are confident that 2023 will see a step change in pace and deliver transformation that colleagues and patients will feel the benefits of day to day in practice.
|
|
|
GOQii and LiberateAI are doing exciting work on Call / Recall, with the opportunity to model demand and capacity for long term condition appointments, automate invites for some routine appointments, display real time data on long term condition care and integrate more effectively with our virtual coaching offer. The complexity of this area means it will take time to see direct impact |
|
|
in our day to day operations, but the potential is significant. In the short term, Edenbridge are working on our health data in order to delivery insights that will help you better understand what is happening in your practices and improve care in a number of areas. |
|
|
In Lewisham and AWC, our teams are deploying Klinik as a total digital access solution, to test whether an effective “digital front door”, can be engineered. To spread best practice, we have authored a “playbook on digital access”, which will be shared once the learning (good and bad!) from AWC and Lewisham is captured. As well as working with Klinik, and meeting with other emerging suppliers of online consultation and access software, we are also deploying Ada’s AI to test whether it can effectively triage musculoskeletal cases.
Much of 2022 was spent doing the “hard yards” – meeting and testing potential suppliers / partners, getting our infrastructure right and building our team. We are confident that 2023 will see a step change in pace and deliver transformation that colleagues and patients will feel the benefits of day to day in practice.
|
|
|
There are a number of research projects that we currently undertake within the partnership. Research while it is more across the partnership, we do support very much a local research at a divisional level.
More recently as a part of research we are doing a quality improvement project of people with Inherited Retinal Dystrophies (IRD).
Novartis - Mendelian IRD Quality Improvement Pilot. Inherited Retinal Dystrophies (IRD) are a group of genetic disorders that can cause significant visual loss or impairment). Historically, there was not much to offer these patients however, advances in genetic testing and emerging treatments in recent years warrant early diagnosis and active management. Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) are two such conditions. Of note, both RP and LCA can arise from variants in a number of different genes. There now exists NICE approved gene therapy for severe and progressive types of RP and LCA.
In the UK, there remain significant disparities in access to genetic testing for IRD patients. Without testing, patients do not have a specific and actionable diagnosis that could unlock treatment options within the NHS. The Objective is to Pilot a nationally scalable, technology-driven approach to identifying “hard-to-reach” patients in a primary care setting who may be appropriate for genetic testing to unlock treatment options. Mendelian has developed a primary care case finding algorithm to flag patients with an existing diagnosis of RP or LCA in electronic health records (deployed via MendelScan, a Class 1 MHRA Medical Device), as part of a Quality Improvement Pilot with Novartis Pharmaceuticals that is to be implemented in the NHS.
|
|
|
|
|
|
|
|
